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Synthesis and X-ray structural characterization of pyridine-2-
carboxaldehyde thiosemicarbazone (L), and its metal complexes, 
[Cu(L)(OH2)](ClO4)2 and [Pb(L)(ONO2)2]n are reported. X-ray 
diffraction reveals that the metal centres in the two complexes are 
distorted square planar and square pyramid geometries, 
respectively. Among the three compounds [Cu(L)(OH2)](ClO4)2 
is found to be active against human keratinocyte cell line. 
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Pharmacological properties of transition metal-
thiosemicarbazone complexes attracted considerable 
attention of chemists during a long period1,2. 
Thiosemicarbazone can bind to metal ions either in its 
neutral thione form (1, Scheme 1) or it can 
tautomerize to its thiolate form (2, Scheme 1) as 
bidentate N,S-donor ligand forming a five membered 
chelate ring at metal centre2b-2d. Introduction of 
additional donor site through the carbonylic  
carbon can increase the donor centres in the ligand 
backbone. Some unusual mode of coordination of 
thiosemicarbazone is also reported in literature3. 
Biological activities of transition metal-
thiosemicarbazone complexes, as we mentioned, have 
also made the compounds promising. These can act as 
antineoplastic, antimalarial, antibacterial, antiviral and 
antifungal2b,4compounds. In 1956, for the first time, 
the anticancer activities of pyridine-2-carboxaldehyde 
thiosemicarbazone was reported by Skipper et al2a. In 
subsequent years, bis(thiosemicarbazone) complexes 
of Cu(I/II) were found to be potential anticancer 
agents5. The ligand thiosemicarbazone has some 
analytical applications as those have strong affinity 
for metal ion binding6. Further, recent research on  
s-, d- and even f-block metal ions are highly focused 
whereas less attention has been paid to the studies of 
p-block metal ions7. As a heavy p-block element, 
Pb(II) with its large radius, flexible coordination 
numbers, varied stereochemical activities is important 
for designing different functional materials7c,7d. 
Considering all these aspects, we have synthesized 
and X-ray crystallographically characterized pyridine-
2-carboxaldehyde thiosemicarbazone (L) which was 
previously reported to be as antileukemic agents2a,  
its new metal complexes [Cu(L)(OH2)](ClO4)2 and 
[Pb(L)(ONO2)2]n. Compound [Cu(L)(OH2)](ClO4)2 is 
found to be cytotoxic against keratinocyte cell lines, 
while L and [Pb(L)(ONO2)2]n have no specificity on 
those cell lines. 
 
Experimental 
Pyridine-2-carboxaldehyde, copper(II) perchlorate 
hexahydrate, lead(II) nitrate were purchased  
from Sigma Aldrich and used as received. 
Thiosemicarbazide was purchased from E. Merck 
India. Solvents were of reagent grade and used 
without further purification. 
Elemental analyses (carbon, hydrogen and nitrogen) 
were performed on a Perkin-Elmer 2400 CHNS/O 
elemental analyzer. UV-vis and IR spectra (KBr discs, 
4000-300 cm-1) were recorded on Shimadzu UV-vis 
2450 spectrophotometer and Perkin-Elmer FT-IR 
(model RX1) spectrometer, respectively. 
The ligand, pyridine-2-carboxaldehyde thio 
semicarbazone (L) was prepared as follows: Ethanolic 
solutions of pyridine-2-carboxaldehyde (8 mmol,  








mixed and refluxed for six hours to yield the 
thiosemicarbazone, L. After cooling, the solution 
turned green and brown crystals of L appeared on 
keeping the solution in open air overnight. Yield: 
0.844 g (87% based on thiosemicarbazide). Anal. (%): 
Calc. for C7H8N4S: C, 46.67; H, 4.47; N, 31.11 
Found: C, 46.20; H, 4.39; N, 31.21. IR cm-1 (KBr): 
1612, 1524, 1460, 1433, 1353. UV-vis (MeOH, nm): 
λmax () at 326 (5710).  
Synthesis of [Cu(L)(OH2)](ClO4)2 was as follows: 
Aqueous ethanolic solution of copper(II) perchlorate 
hexahydrate (1 mmol, 0.30 g) was added dropwise to 
the ligand L (1 mmol, 0.20 g) in ethanol with stirring. 
The greenish brown coloured ligand solution changed 
to deep green. Keeping the solution in open air for 
about 60 days yielded green coloured block shaped 
diffraction-quality single crystals of complex 
[Cu(L)(OH2)](ClO4)2. Yield 0.225 g (75% based on 
metal salt). Anal. (%): Calc. for C7H14N4O11SCl2Cu: 
C, 16.91; H, 2.84; N, 11.27 Found: C, 16.02; H, 2.79; 
N, 11.20. IR cm-1 (KBr): 3252, 1627, 1392, 1048. 
UV-vis (MeOH, nm): λmax () at 293 (60160), 323 
(45680), 402 (24760). 
Synthesis of [Pb(L)(ONO2)2]n was as follows: 
The gradual mixing of ethanolic solution of lead(II) 
nitrate tetrahydrate (1 mmol, 0.30 g) and L  
(1 mmol, 0.2 g) in ethanol with gentle heating and 
stirring resulted in a yellow solution mixture. The 
mixture was then kept in open air for slow 
evaporation. Yellow coloured block shaped crystals 
of [Pb(L)(ONO2)2]n appeared after about 60-65 
days. Yield: 0.216 g (72% based on metal salt). 
Anal. (%): Calc. for C7H8N6O6SPb: C, 16.43; H, 
1.57; N, 16.43 Found: C, 16.52; H, 1.50; N,  
15.99. IR cm-1 (KBr): 1575, 1382, 1030. UV-vis 
(MeOH, nm): λmax () at 327 (13800). 
Single crystal X-ray diffraction data were 
collected using a Rigaku XtaLABmini 
diffractometer equipped with mercury CCD 
detector. The data were collected with graphite 
monochromated Mo-Kα radiation (λ = 0.71073 Å) 
at 100 K using  scans. The data were reduced 
using Crystal Clear suite 2.08 and the space group 
determination was done using Olex29. The structure 
was resolved by direct method and refined by  
full-matrix least-squares procedures using the 
SHELXL10 package using OLEX2 suite. The crystal 
data and refinement details are listed in Table 1.  
All the figures have been generated using  
ORTEP-3211. 
Results and discussion 
Ligand (L) was prepared by refluxing pyridine- 
2-carboxaldehyde and thiosemicarbazide in  
ethanol. Complexes [Cu(L)(OH2)](ClO4)2 and 
[Pb(L)(ONO2)2]n were prepared by mixing copper(II) 
perchlorate hexahydrate and lead(II) nitrate, 
respectively with the ligand. L and its two complexes 
are soluble in CH3CN and DMSO. IR spectrum of L 
(Supplementary data, Fig. S1) exhibits a band at  
2923 cm-1 indicating (-NH-) stretching frequency. A 
strong band at 1353 cm-1 in L is assigned to (C-N). 
This band is shifted to some higher frequencies in its 
metal complexes (Supplementary data, Figs S2 and 
S3). This shifting of (C-N) frequencies to higher 
value is attributed to the deprotonation of the  
-nitrogen atom in the ligand framework making some 
elongation the C-N bond. Band at ~1030-1060 cm-1 in 
the ligand and metal complexes arises because of the 
(C=S) frequencies. Band at ~1600 cm-1 is because of 
imine bond in the structures12. The ligand and each of 
the complexes were X-ray crystallographically 
characterized (Tables 1, 2, 3, 4).  
The thermal ellipsoid probability plots of L, 
[Cu(L)(OH2)](ClO4)2 and [Pb(L)(ONO2)2]n are given 
in Figs 1-3. L is found to be in its normal thione form 
(C-S, 1.65 Å (1) (Table 2), Scheme 1) with four 
molecules in the asymmetric unit and crystallized in 
monoclinic non-centrosymmetric Pc space group. 
From the bond angle-bond distance data (Table 3) the 
Cu(II) centre in [Cu(L)(OH2)](ClO4)2 is found to be  
in a distorted square planar geometry. Upon 
coordination with Cu(II), L is in its thione form (C-S, 
1.71 Å (1), Scheme 1) with minor elongation in the  
C-S bond. Among the four corners of the square plane, 
three come from the ligand framework (one pyridine 
nitrogen, N1; one imine nitrogen, N2; and one thione, 
S1) and the fourth coordination site is occupied by a 
water molecule. The bond distances are also very 
close. The deviation between maximum and minimum 
bond distances is 0.343 Å. Coordination geometry of 
Pb(II) of [Pb(L)(ONO2)2]n is best described as 
distorted square pyramid as exemplified by its  value 
(= 0.21)13. Considering bond angle-bond distance data 
(Table 4), pyridine and imine nitrogen from the L and 
two oxygen atoms from two different nitrates form 
the basal plane. The thione sulphur resides in its axial 
position. Here the equatorial bond distances range 
from 2.54-2.88 Å ( = 0.34 Å). The Pb(1)-S(1) bond 
distance is 2.90 Å. This compound is assumed to be a 
neutral polymer as firstly, there is no charge balancing 




counter anion in its X-ray structure and secondly, the 
ligand is in its neutral form 1 (Scheme 1) with thione 
group (C-S bond distance in L, 1.64 Å (Table 2) and 
in [Pb(L)(ONO2)2]n, 1.68 Å (Table 4)). As the ligand 
is neutral, the +2 formal charge on Pb in each unit  of 
the polymer is neutralized by the two coordinated 
nitrate groups. As Pb(II) is larger than Cu(II) in terms 
of atomic size, it prefers higher coordination number. 
As a result the counter anion nitrate which was 
present with the starting Pb(II) salt is found 
coordinated with the Pb(II)L moiety. The appended 
oxygen atoms of the metal bound nitrates bind  
with different Pb(II)L moieties to make it a  
polymeric chain.  
All the three compounds L, [Cu(L)(OH2)](ClO4)2 
and [Pb(L)(ONO2)2]n were investigated for 
cytotoxic activity.  L and [Pb(L)(ONO2)2]n  did  not 
Table 3 — Bond lengths (Å) and bond angles (°) of 
[Cu(L)(OH2)](ClO4)2 
Bond lengths    
Cu(1)-N(1) 2.013(2) Cu(1)-S(1) 2.2787(8) 
Cu(1)-N(2) 1.940(2) Cu(1)-O(9) 1.935(2) 
Bond angles    
N(1)-Cu(1)-N(2) 80.45(9) N(1)-Cu(1)-O(9) 96.15(10) 
N(2)-Cu(1)-S(1) 85.17(7) N(1)-Cu(1)-S(1) 165.62(7) 
O(9)-Cu(1)-S(1) 98.21(7) N(2)-Cu(1)-O(9) 175.98(10) 
Table 2 — Bond lengths (Å) and bond angles (°) of L 
Bond lengths    
C(1)-C(2) 1.42(2) C(1)-C(6) 1.41(2) 
C(2)-C(3) 1.37(2) C(6)-N(2) 1.275(18) 
C(3)-C(4) 1.39(2) N(2)-N(3) 1.378(17) 
C(4)- C(5) 1.41(2) N(3)-C(7) 1.347(18) 
C(5)-N(1) 1.30(2) C(7)-N(4) 1.343(18) 
C(1)-N(1) 1.308(18) C(7)-S(1) 1.640(15) 
Bond angles    
N(1)-C(1)-C(6) 116.5(14) N(3)-C(7)-N(4) 114.6(13) 
C(1)-C(6)-N(2) 123.8(14) N(4)-C(7)-S(1) 123.9(12) 
C(6)-N(2)-N(3) 117.3(12) N(3)-C(7)-S(1) 121.4(12) 
N(2)-N(3)-C(7) 122.8(12)   
Table 1 — Crystal data and structure refinement parameters of L, [Cu(L)(OH2)](ClO4)2 and [Pb(L)(ONO2)2]n 
Parameters L [Cu(L)(OH2)](ClO4)2 [Pb(L)(ONO2)2]n 
Emperical formula C7H8N4S C7H14N4O11SCl2Cu C7H8N6O6SPb 
Formula weight 180.24 496.74 779.51 
T (K) 293 293 100 
Wavelength (Å) 0.71073 0.71073 0.71073 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group P1c1 P121/c 1 P2ybc 
Unit cell dimensions    
a (Å) 17.410(6) 12.9545(11) 21.7273(14) 
b (Å) 4.7899(19) 9.7618(6) 6.9192(4) 
c (Å) 20.691(7) 14.9853(12) 19.0657(13) 
α (˚) 90 90 90 
β (˚) 90.170(16) 111.582(3) 115.385(2) 
γ (˚) 90 90 90 
V (Å3) 1725.5(11) 1762.2(2) 2589.5(3) 
Z  8 4 4 
Dcalc (mg m
-3) 1.388 1.872 2.624 
Absorption coeff. (mm-1) 0.323 1.724 13.232 
F(000) 752 1004 1904 
Crystal size (mm3) 0.25 × 0.14 × 0.1 0.3 × 0.3 × 0.2 0.21 × 0.18 × 0.12 
Theta range for data collection (°) 3.054 - 27.540 2.548 - 27.492 2.137 - 27.483 
Index ranges -22 ≤ h ≤ 22, -6 ≤ k ≤6, 
 -26 ≤ l ≤25 
-16 ≤ h ≤ 16, -12 ≤ k ≤12,  
-19 ≤ l ≤19 
-28 ≤ h ≤ 28, -8 ≤ k ≤8, -24 ≤ l 
≤24 
Reflections collected 13425 13519 26693 
Independent reflections 7519 [Rint = 0.1194] 4004 [Rint = 0.0438] 5908 [Rint = 0.1365] 
Completeness of theta 99.7% [θ = 25.242] 98.7% [θ = 25.242] 99.5% [θ = 25.242] 
Absorption correction Multi-scan Multi-scan Multi-scan 
Tmax and Tmin 1.000 and 0.707 1.000 and 0.847 1.000 and 0.802 
Refinement method Full matrix Full matrix Full matrix 
Data/restrains/parameters 7519/2/ 436 4004/0/ 255 5908/0/ 379 
Goodness-of fit (GOF) F2 0.987 1.024 1.115 
Final R index [l >2σ(l)] R1 = 0.1031 and wR2 = 0.2498 R1 = 0.0421 and wR2 = 0.1149 R1 = 0.0527 and wR2 = 0.1395 
R index (all data) R1 = 0.1949 and wR2 = 0.3430 R1 = 0.0529 and wR2 = 0.1259 R1 = 0.0573 and wR2 = 0.1423 
Largest difference between  
peak and hole (e Å-3) 






Table 4 — Bond lengths (Å) and bond angles (°) of 
[Pb(L)(ONO2)2]n 
Bond lengths    
Pb(1)-O(1) 2.547(10) Pb(2)-O(5) 2.702(10) 
Pb(1)-N(1) 2.690(11) Pb(2)-N(5) 2.677(9) 
Pb(1)-N(2) 2.631(10) Pb(2)-N(6) 2.640(8) 
Pb(1)-S(1) 2.901(3) Pb(2)-S(2) 2.890(3) 
Pb(2)-O(4) 2.582(10)   
Bond angles    
O(1)-Pb(1)-N(1) 69.2(3) O(4)-Pb(2)-N(6) 79.3(4) 
O(1)-Pb(1)-N(2) 76.6(3) O(4)-Pb(2)-S(2) 99.5(3) 
O(1)-Pb(1)-S(1) 98.9(3) O(5)-Pb(2)-N(5) 76.8(3) 
N(1)-Pb(1)-N(2) 62.2(3) O(5)-Pb(2)-N(6) 70.5(3) 
N(1)-Pb(1)-S(1) 127.8(2) O(5)-Pb(2)-S(2) 91.3(3) 
N(2)-Pb(1)-S(1) 65.6(2) N(5)-Pb(2)-N(6) 62.1(3) 
O(4)-Pb(2)-O(5)  140.3(3) N(5)-Pb(2)-S(2) 127.7(2) 













Fig. 3 — ORTEP of [Pb(L)(ONO2)2]n with 20% ellipsoid probability. 
 
 
Fig. 4 — Cytotoxic activity of synthesized pyridine-2-
carboxaldehyde thiosemicarbazone and its Pb and Cu complexes. 
[(a) L, (b) [Pb(L)(ONO2)2] and (c) [Cu(L)(OH2)](ClO4)2]. 




show any specificity, but [Cu(L)(OH2)](ClO4)2 
showed selectivity against cancer cells compared to 
normal keratinocytes (Fig. 4). The IC50 value of the 
complex against normal cell was 7.5 M and IC50 
for cancer cell was 5.0 M. 
Herein, we have reported the synthesis and  
X-ray crystallographic characterization of pyridine-2-
carboxaldehyde thiosemicarbazone (L), [Cu(L)(OH2)] 
(ClO4)2 and [Pb(L)(ONO2)2]n. Polymeric nature of the 
Pb complex is due to larger size of the metal as well as 
its preference for higher coordination number. Cu(II) 
complex of L [Cu(L)(OH2)](ClO4)2 was active against 
keratinocyte cell lines. However, no specificity was 
observed for L and [Pb(L)(ONO2)2]n. The IC50 value of 
[Cu(L)(OH2)](ClO4)2 against normal and cancer cells 
was 7.5 M and 5.0 M, respectively, which indicates 
that the complex has the potential to be explored further 
for anti-cancer activity. 
 
Supplementary data 
CCDC 1519838, 1519844 and 1524581 contain  
the supplementary crystallographic data for L, 
[Cu(L)(OH2)](ClO4)2 and [Pb(L)(ONO2)2]n, respectively. 
These data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk/conts/retrieving.html, or 
from the Cambridge Crystallographic Data Centre, 12 
Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 
1223-336-033; or e-mail: deposit@ccdc.cam.ac.uk. 
Other supplementary data associated with  
this article i.e., Figs S1-S3 and cif files, are  
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